Retatrutide simultaneously activates three receptor pathways GLP-1, GIP, and glucagon producing additive metabolic effects no single or dual agonist achieves alone
Because it remains under study, its dosing, approved uses, and safety profile have not been established by an FDA-approved label
coexistence of nevus and desmoplastic trichoepithelioma is occasionally encountered
Market in 2008 and is now available only as a compounded preparation
Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
DavisJLParisHLBealsJWBinnsSEGiordanoGRScalzoRLet al